Feasibility and acceptability of telehealth and contactless HPV self- testing for Māori and Pacific women during a COVID-19 outbreak in New Zealand

THE RESEARCH TEAM

Dr Karen Bartholomew^{1,2}. Jane Grant^{1,2}. Anna Maxwell^{1,2}. Fiona Gillett^{1,2}, Dr Rajneeta Saraf^{1,2}, Dr Georgina McPherson². Dr Deralie Flower¹. Dr Jvoti Kathuria³. Dr Nina Scott^{4,5}, Dr Collette Bromhead⁶, Kate Moodabe⁷, Susan M Sherman⁸, Professor Sue Crengle⁹, Dr Richard Massey¹⁰,

¹ Te Toka Tumai, Auckland, Te Whatu Ora, ² Waitematā Te Whatu Ora, ³ Counties Manukau Te Whatu Ora, 4 Waikato Te Whatu Ora, 5 University of Auckland, ⁶ Massey University, ⁷ Total Healthcare, ⁸ Keele University, ⁹ University of Otago, 10 Pathlab, 11 AwhiMai Consultancy


Four of the authors are Māori, and one is Pacific. We are supported by a Māoriled steering group (Chair Professor Sue Crengle) and advisors. We acknowledge the National Cervical Screening Programme, National Kaitiaki Group members for their approval of Māori women's data. We thank Mellissa Murray, Marara Metekingi and Miriam Gabriel for contacting women and undertaking contactless deliveries. Thanks to Dr Mahesh Patel, Rachael Scully, staff of the participating Tāmaki Health Local Doctors clinics, and the women who took part in our study. The study was supported by the Māori Health Pipeline and funding from Waitematā, Te Toka Tumai Auckland, Counties Manukau districts, and Total Healthcare Tāmaki Health.

BACKGROUND

- Approximately 160 cases of cervical cancer are reported annually in Aotearoa New Zealand, with higher rates in Māori and Pacific women. 1-2
- Only 12% of affected women from 2012-2017 had been adequately screened,3 with substantially lower coverage for Māori, Pacific and Asian women.4 COVID-19 has impacted the delivery of primary care and preventative healthcare.
- Self-testing is an acceptable solution that improves equity, and telehealth could facilitate continued screening. 5-6 However, any technology may have equity impacts.

Conduct a small proof-of-concept study to determine the feasibility and acceptability for Māori and Pacific women of a telehealth offer and contactless delivery of human papillomavirus (HPV) cervical screening selftest during the 2021 COVID-19 Level 4 lockdown in Auckland, New Zealand.

Fig 1. Flow diagram showing eligibility and uptake of self-test offer



- A cohort of 197 eligible Māori and Pacific women were invited.
- Sixty-six women agreed to take part. Five were subsequently found to be ineligible. After one round of follow up 92 women (65.7%) were not able to be reached.
- Overall uptake was 61 samples returned (31.8%), and uptake of all contactable women was 70.9%.
- Six of the 61 HPV self-tests (9.8%) were positive and were followed up.

RESULTS

"Being comfortable in myself doing the self-screening and not feeling embarrassed. Thank you for the opportunity of self-respect"

Māori participant, 40–45 years

Table 1. Participant demographics

П				
	Characteristic	Overall	Māori	Pacific
	Total eligible (%)	197	86 (43.7)	111 (56.3)
	Median age (years)	43 (35-51)	42 (34-50)	43 (34-52)
	Age group (%)			
	30-39 years	86 (43.7)	38 (46.0)	48 (43.2)
	40-49 years	51 (25.9)	21 (26.0)	30 (27.0)
	50-59 years	38 (19.3)	11 (19.0)	27 (24.3)
	60-69 years	22 (11.2)	16 (9.0)	6 (5.4)
	Duoviava sausanina histor	m. (9/)		
	Previous screening histor		24 (24 4)	EQ (4E Q)
	Due	71 (36.0)	21 (24.4)	50 (45.0)
	Overdue	114 (57.9)	60 (69.8)	54 (48.6)
	Never screened	12 (6.1)	5 (5.8)	7 (6.4)

"I was relaxed when I did the test at home"

Pacific participant, 40-45 years

"This was a great experience, my wish is that that is available to all women, this will save lots of lives. It was easy, most women will do it"

Māori participant, 50-55 years

METHOD

The eligibility criteria included those enrolled in a Local Doctors Tāmaki Health Clinic, aged 30-69, and due for cervical cancer screening. A total of 197 women were invited by text for an HPV self-test, and non-responders were followed up with a single phone call attempt. Self-test kits were delivered without contact, and samples were tested for oncogenic HPV types using the BD Onclarity HPV Test. Invalid results were recorded, and a repeat test was offered to the participant; negative test results were texted to women with advice to return for a routine cervical screen in five years, while HPV-positive results were communicated via a telehealth contact. Post-test questionnaires were sent via text link, and descriptive analyses were used to describe the proportion of participating women by age, ethnicity, screening status, and HPV results.

REFERENCES

¹ Ministry of Health. Cancer: New registrations and deaths 2013. Wellington: Ministry of Health; 2016. Available from: https://www.health.govt.nz/publication/ cancer-new-registrations-and-deaths-2013

² Brewer N, Pearce N, Jeffreys M, Borman B, Ellison-Loschmann L. Does screening history explain the ethnic differences in stage at diagnosis of cervical cancer in New Zealand? Int J Epidemiol. 2010;39(1):156-65. http://doi:10.1093/ije/dyp303 ³University of Otago, for the Ministry of Health. Review of Cervical Cancer Occurrences in relation to Screening History in New Zealand for the years 2013-2017. Available at: https://www.nsu.govt.nz/publications/review-cervical-canceroccurrences-relation-screening-history-new-zealand-years-2013-2017

⁴ Coverage data is from the National Cervical Screening Programme Coverage Report. Interactive tool prepared by Ministry of Health. Available at: https://minhealthnz.shinyapps.io/nsu-ncsp-coverage 10 Feb 2022. 5 Adcock A, Cram F, Lawton B, et al. Acceptability of self-taken vaginal HPV sample

for cervical screening among an under-screened Indigenous population. Aust N Z J Obstet Gynaecol. 2019;59:301-7. https://doi:10.1111/ajo.12933

⁶ Brewer N, Bartholomew K, Grant J, et al. Acceptability of human papillomavirus (HPV) self-sampling among never- and underscreened Indigenous and other minority women: a randomised three-arm community trial in Aotearoa New Zealand. Lancet Reg Health West Pac. 2021 Sep 7:16(100265);1-10. https://doi.org/10.1016/j.lanwpc.2021.100265

CONCLUSION

- The offer of HPV self-testing during the COVID-19 lockdown was feasible and highly acceptable for Māori and Pacific women.
- Importantly, HPV self-testing via telehealth and mail-out, alongside other options, offers a potential pro-equity approach for addressing the impact of deferred screens due to COVID-19 and other longstanding coverage issues.

Bartholomew K, Grant J, Maxwell A, Bromhead C, Gillett F et al. Feasibility and acceptability of telehealth and contactless delivery of human papillomavirus (HPV) self-testing for cervical screening with Maori and Pacific women in a COVID-19 outbreak in Aotearoa New Zealand.. NZMJ 2022, 11;135(1565):83-94.